TNX-1300 (double-mutant cocaine esterase) — FDA meeting
2026
The Company plans to meet with the FDA in 2026 to inform the clinical design of the next Phase 2 study (a Phase 2 study has been completed).Source filing
TNXP biotech catalysts & pipeline
TONIX PHARMACEUTICALS HOLDING CORP · Data as of 2026-10-25
Upcoming catalysts
TNX-102 SL (sublingual cyclobenzaprine HCl) — Topline data
mid-2027
Topline data is expected to be reported mid-2027.Source filing
Tonmya (cyclobenzaprine hydrochloride sublingual tablets) — Conference presentation
Oct 27
Tonix Pharmaceuticals Holding Corp. BERKELEY HEIGHTS, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial-stage biopharmaceutical company, today announced a poster examining the effects of TONMYA® (cyclobenzaprine HCl sublingual tablets) on fibromyalgia symptoms and physical function will be presented at the International Association for the Study of Pain (IASP) 2026 World Congress on Pain, held October 26-30, 2026, in Bangkok, Thailand.Source filing